Ad-hoc | 26 March 2007 20:04
STRATEC Biomedical Systems AG / Dividend
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
STRATEC raises dividend by 50%
Birkenfeld, March 26, 2007
The Supervisory and Management Boards of STRATEC Biomedical Systems AG
decided at their meeting on March 26, 2007 to propose to the Annual General
Meeting held on May 16, 2007 that a dividend of Euro 0.15 per share be
distributed to shareholders for the 2006 financial year (previous year:
Euro 0.10, following issue of bonus shares). Subject to the consent of the
Annual General Meeting, the company would then have raised its distribution
by 50% compared with the previous year, an increase which
is equivalent to the development in consolidated earnings.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
The increase in the distribution proposed by the Supervisory and Management
Boards is intended to enable shareholders to participate in the superb
earnings performance of the STRATEC Group in the 2006 financial year.
The Management Board will be presenting the consolidated financial
statements for 2006 within the framework of its Annual Results Telephone
Conference on April 4, 2007 (conference language: German). Press
representatives, investors and analysts who would like to take part in this
telephone conference are requested to register for this purpose with our
Investor Relations Team, Tel: +49 (0)7082 7916-190.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories and research
institutes around the world. The company develops its products on the basis
of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-mail: ir@stratec-biomedical.de
DGAP 26.03.2007
----------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
www: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------